Burning Rock Announces Pricing of Upsized Registered Secondary Public Offering of American Depositary Shares
Rhea-AI Summary
Burning Rock Biotech Limited (NASDAQ: BNR) announced a secondary public offering of 2,243,000 American Depositary Shares (ADSs) priced at $25.75 each, totaling approximately $57.8 million. The offering comes from selling shareholders, with no proceeds going to the Company. The underwriters, including Morgan Stanley, BofA Securities, and Cowen, have the option to purchase an additional 336,450 ADSs within 30 days. This registration statement was filed with the SEC and became effective on December 3, 2020.
Positive
- The secondary offering size is approximately $57.8 million.
- The Company continues to lead in NGS-based therapy selection testing in China.
Negative
- No proceeds from the offering will benefit Burning Rock, potentially limiting financial impact.
- The offering could lead to shareholder dilution if additional ADSs are purchased by underwriters.
News Market Reaction 1 Alert
On the day this news was published, BNR declined 2.07%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
GUANGZHOU, China, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced the pricing of an upsized secondary public offering by certain selling shareholders (the “Offering”) of 2,243,000 American Depositary Shares (“ADSs”), each representing one Class A ordinary share of the Company, at a public offering price of US
The Company will not receive any proceeds from the sale of the ADSs by the selling shareholders.
Morgan Stanley & Co. LLC, BofA Securities, Inc. and Cowen and Company, LLC are acting as joint bookrunners for the Offering.
The Offering is being made only by means of a prospectus forming part of the effective registration statement. A copy of the prospectus relating to the Offering may be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, New York, NY 10014, via telephone: 1-917-606-8487, or via email: prospectus@morganstanley.com; BofA Securities, Inc., Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, via email: dg.prospectus_requests@bofa.com; and Cowen and Company, LLC, Attention: Prospectus Department, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: 1-833-297-2926, or via email: PostSaleManualRequests@broadridge.com.
A registration statement on Form F-1 was initially filed with the U.S. Securities and Exchange Commission (“SEC”) on December 1, 2020, and has been declared effective on December 3, 2020. An additional registration statement on Form F-1 was filed with the SEC pursuant to Rule 462(b) and became automatically effective on December 3, 2020. This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, the securities of the Company described herein, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
FAQ
What is the size of the secondary offering for BNR?
Who are the underwriters for BNR's secondary offering?
What is the public offering price for BNR's ADSs?
Will Burning Rock receive any proceeds from the offering?
